Skip to main content
All lobbying clients

VERTEX PHARMACEUTICALS INCORPORATED

Lobbying client · Massachusetts · filed 2025 to 2026

Biopharmaceutical Company

$12,425,000 Reported spend
94 Filings counted
13 Outside firms hired
19 Bills named

Spend is reported income plus in-house expenses across 94 filings. 1 further filing for this client was restated by a later amendment and is left out of every total here. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 14 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as VERTEX PHARMACEUTICALS.

 Who filed for this client 14

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 19
  • H.R. 1227
    Alternatives to PAIN Act
    50 filings
  • S. 475
    Alternatives to PAIN Act
    41 filings
  • S. 864
    HELP Copays Act
    7 filings
  • H.R. 1414
    Cameron’s Law
    6 filings
  • H.R. 1518
    New Era of Preventing End-Stage Kidney Disease Act
    6 filings
  • H.R. 7142
    Alternatives to PAIN Act
    5 filings
  • S. 3832
    Alternatives to PAIN Act
    5 filings
  • H.R. 6423
    HELP Copays Act
    4 filings
  • S. 375
    Transition-to-Success Mentoring Act
    3 filings
  • H.R. 1
    One Big Beautiful Bill Act
    2 filings
  • H.R. 1672
    Maintaining Investments in New Innovation Act
    2 filings
  • H.R. 2484
    Seniors’ Access to Critical Medications Act of 2025
    2 filings
  • H.R. 3838
    Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fisc…
    2 filings
  • H.R. 946
    ORPHAN Cures Act
    2 filings
  • S. 2296
    National Defense Authorization Act for Fiscal Year 2026
    2 filings
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth…
    1 filing
  • H.R. 1968
    Full-Year Continuing Appropriations and Extensions Act, 2025
    1 filing
  • S. 1862
    ORPHAN Cures Act
    1 filing
  • S. 891
    Bipartisan Health Care Act
    1 filing
 Reported by year 2 years
  • 2026 $5,260,000 42 filings
  • 2025 $7,165,000 52 filings
 Issues lobbied 10

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 15
  • HOUSE OF REPRESENTATIVES 80
  • SENATE 80
  • Health & Human Services, Dept of (HHS) 30
  • White House Office 26
  • Centers For Medicare and Medicaid Services (CMS) 21
  • Food & Drug Administration (FDA) 12
  • U.S. Trade Representative (USTR) 8
  • Congressional Budget Office (CBO) 7
  • Office of Management & Budget (OMB) 7
  • Commerce, Dept of (DOC) 5
  • Vice President of the U.S. 5
  • Executive Office of the President (EOP) 4
  • Natl Economic Council (NEC) 3
  • State, Dept of (DOS) 2
  • Patent & Trademark Office (PTO) 1
 Recent filings 95 total
Q3 report
CGCN GROUP, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
MARSHALL & POPP, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
MCLARTY INBOUND LLC
3rd Quarter 2026 (July 1 - Sep 30) · $90,000 income · posted Oct 20, 2026
View →
Q3 report
AVENUE SOLUTIONS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
TARPLIN, DOWNS & YOUNG, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $80,000 income · posted Oct 20, 2026
View →
Q3 report
ALSTON & BIRD LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
STANTON PARK GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
ALB SOLUTIONS
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View →
Q3 report
TIBER CREEK GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $60,000 income · posted Oct 20, 2026
View →
Q3 report
EMPIRE CONSULTING GROUP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 19, 2026
View →
Q3 report
VERTEX PHARMACEUTICALS INCORPORATED
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $1,100,000 expenses · posted Oct 19, 2026
View →
Q3 report
CROSSROADS STRATEGIES, LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 17, 2026
View →
Registration amendment
MCLARTY INBOUND LLC
1st Quarter 2025 (Jan 1 - Mar 31) · posted Oct 7, 2026
View →
Q3 report
HOLLAND & KNIGHT LLP
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $20,000 income · posted Oct 7, 2026
View →
Q2 report
ALSTON & BIRD LLP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 reportNo activity
MCLARTY INBOUND LLC
2nd Quarter 2026 (Apr 1 - June 30) · posted Jul 20, 2026
View →
Q2 report
STANTON PARK GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View →
Q2 report
AVENUE SOLUTIONS
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 20, 2026
View →
Q2 report
CGCN GROUP, LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 19, 2026
View →
Q2 report
TIBER CREEK GROUP
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $60,000 income · posted Jul 18, 2026
View →

Showing the 20 most recent of 95 filings. Search the explorer for "VERTEX PHARMACEUTICALS INCORPORATED".

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem